Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-31
2005-05-31
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S239200, C514S330000, C514S537000, C514S626000, C514S653000, C564S362000, C564S364000, C564S365000
Reexamination Certificate
active
06900203
ABSTRACT:
(R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure:wherein R1, R2, and R4are independently selected from —H or —F, at least one of R1, R2, and R4is —F, and R3is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme™-H series biocatalysts) is disclosed. Several such biocatalysts are disclosed.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5719197 (1998-02-01), Kanios et al.
Kirk et al., “Synthesis and Biological Properties of 2-, 5-, and 6-Fluoronorepinephrines,”J. Med. Chem1979, 22, 1493-1497.
Kirk, “Fluorine-Substituted Neuroactive Amines,”In Selective Fluorination in Organic and Bioorganic Chemistry(Welch, J.T. ed) ACS Symposium Series 456, American Chemical Society: Washington, D.C., 1991, pp. 136-155.
Jastak et al., “Vasoconstrictors and local anesthesia: a review and rationale for use,”J. Am. Dent. Assoc.1983, 107, 623-630.
Markovich et al., “Synthesis of Halogenated Trimetoquinol Derivatives and Evaluation of Their β-Agonist and Thromboxane A2(TXA2) Antagonist Activities,”J. Med. Chem.1992, 35, 466-479.
Brown et al., “Solubility of Hydrogen Chloride at Low Temperatures. A Measure of the Basic Properties of Aromatic Nuclei; -and σ- Complexes and Their Role in Aromatic Substitution, ”J. Am. Chem. Soc.1952, 74, 3570-3576.
Arasaratnam, et al., “Reversibly soluble biocatalyst: optimization of trypsin coupling to Eudragit S-100 and biocatalyst activity in soluble and precipitated forms,”Enz. Microb. Technol.2000, 27, 254-263.
Effenberger et al., “Stereoselective synthesis of thienyl and furyl analogues of ephedrine,”Tetrahedron: Asymmetry,(1997) 8, 469-476.
Effenberger et al., “Synthesis of the Adrenergic Bronchodilators (R)-Terbutaline and (R)-Salbutamol from (R)-Cyanohydrins,”J. Org. Chem.1997, 62, 3867-3873.
Kiljunen et al., “(R)- and (S)-Cyanohydrins Using Oxynitrilases in Whole Cells,”Tetrahedron: Asymmetry1996, 7, 1105-1116.
Zandbergen et al., “Synthesis of Optically Active Cyanohydrins Using Almond Meal,”Synth. Commun.1991, 21, 1387-1391.
Smithskamp-Wilms et al., “Hydroxynitrile lyases from almond and sorghum as biocatalysts,”Rec. Trav. Chim. Pays-Bas1991, 110, 209-215.
Becker et al., “Zur Kenntnis der Cyanhydrinsynthese II,”Biochem. Z.1963, 337, 156-166.
Franz Effenberger, “Hydroxynitrile Lyases in Stereoselective Synthesis,”Stereoselective Biocatalysis,(Patel, R.N., ed.), Marcel Dekker, 2000, pp. 321-342.
Brussee et al., “Biocatalysis in the Enantioselective Formation of Chiral Cyanohydrins, Valuable Building Block in Organic Synthesis,”Stereoselective Biocatalysis(Patel, R.N., ed.), Marcel Dekker, 2000, pp. 289-320.
Schmidt et al., “Oxynitrilases: From Cyanogenesis to Asymmetric Synthesis,”Biocatalysis—From Discovery to Application(Fessner, W.D., ed.), Springer, 1999, pp. 193-226.
Effenberger et al., “(R)-Oxynitrilase Catalyzed Synthesis of (R)-Ketone Cyanohydrins,”Tetrahedron: Asymmetry1995, 6, 2945-2952.
Effenberger et al. “Enzyme-catalyzed Synthesis of (R) -Ketone-Cyanhohydrins and Their Hydrolysis to (R) -α-Hydroxy-α-Methyl-Carboxylic Acids,”Tetrahedron Lett.1991, 32, 2605-2608.
Warmerdam et al., “Synthesis of (R)- and (S)-2-hydroxy-3-enoic acid esters,”Recl. Trav. Chim. Pays-Bas1996, 115, 20-24.
Huuhtanen et al., “Enzyme-Catalysed Synthesis of Optically Active Aliphatic Cyanohydrins,”Tetrahedron: Asymmetry1992, 3, 1223-1226.
Belokon et al., “Asymmetric addition of trimethylsilyl cyanide to aldehydes catalysed by chiral (salen)TiIVcomplexes,”Chem. Soc., Perkin Trans. I1997, 1293-1295.
Adejare et al., “Syntheses and Adrenergic Activities of Ring-Fluorinated Epinephrines,”J. Med. Chem.1988, 31, 1972-1977.
Meier et al., “[abc]-Annealated [18]Annulenes,”J. Org. Chem.1992, 57, 6847-6852.
Kirk et al., “Synthesis and Adrenergic Activity of Ring-Fluorinated Phenylephrines,”J. Med. Chem.1986, 29, 1982-1988.
Lu et al., “Syntheses of (R)- and (S)-2- and 6-Fluoronorepinephrine and (R)- and (S)-2- and 6-Fluoroepinephrine: Effect of Stereochemistry on Fluorine-Induced Adrenergic Selectives,”J. Med. Chem.2000, 43, 1611-1619.
Daniel Venter, “The Acid-catalysed Racemisation Mechanism of Catecholamines,”Tetrahedron1991, 47, 5019-5024.
Madden et al., “The Range of Medication Storage Temperatures In Aeromedical Emergency Medical Services,”Prehospital Emergency Care1999, 3, 27-30.
Schmidt et al., “Preparation of Optically Active Cyanohydrins Using the (S)-Hydroxynitrile Lyas fromHevea brasiliensis,” Tetrahedron1996, 52, 7833-7840.
Hondrom, S. O.; Seng, G. E.; Rebert, N. W.Anesthesia and Pain Control in Dentistry1993, 2, 198-202.
Cancañón, F.; Paulus, B. F.; Thompson, g. A.; Ammann, J. R. Investigation of Vasoconstrictor Degradation in Local Anesthetic Injections 30th Annual Meeting & Exhibition of the AADR and 25th Annual Meeting of the CADR, Chicago, 2001.
Gregory, R. J. H.Chem. Rev.1999, 99, 3649-3682.
Furlano, D.; Kirk, K. K.J. Org. Chem.1986, 51, 4073-4075.
Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985) and “Modern Pharmaceutics,” Marcel Dekker, Inc. 3.sup.rd Ed. (G. S. Banker & C. T. Rhodes, Eds.) (copy not enclosed).
J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992).
P. J. Kuzma et al, Regional Anesthesia 22 (6): 543-551 (1997).
Gololobov Mikhail Y.
Lenox Hamilton J.
Terentieva Elena
McAndrews Held & Malloy
O'Sullivan Peter
Polium Technologies, Inc.
LandOfFree
Optically active fluorinated vasoconstrictors, methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optically active fluorinated vasoconstrictors, methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optically active fluorinated vasoconstrictors, methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409053